ESTRO 2024 - Abstract Book

S1100

Clinical - Gynaecology

ESTRO 2024

EBRT Fractionation Schedule

45 Gy in 20 fr / 1 fr per day / 5 fr per week / over 4 weeks

Concurrent Chemotherapy

N(%)

Cisplatin Carboplatin

79 (84) 15 (16)

Brachytherapy Schedule

N(%)

7 Gy x 3 fr 9Gy x 2 fr

55 (58.5) 39 (41.5)

Median OTT (weeks)

7 weeks (Range: 6 to 12)

Median follow-up (months)

65.5 months (range: 7-113)

5-year OS 5-year DFS

67.02% 77.65%

Conclusion:

In conclusion, this study underscores the efficacy and safety of moderately hypo-fractionated radiotherapy with concurrent chemotherapy for locally advanced cervical carcinoma. We observed a 5-year OS of 67.02% and a DFS of 77.65%. Importantly, severe treatment-related toxicities were infrequent and manageable. These findings support the viability of this treatment regimen as a promising option for these patients to reduce OTT and enhance the radiobiological effectiveness of the treatment. Further prospective research and larger studies will be valuable for solidifying these results and optimizing treatment strategies.

Keywords: Cervix, hypofractionation, Radiotherapy

References:

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. 2. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M., et al., Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta analysis. Lancet. 2001;358(9284):781-6. 3. Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000;48(1):201-11.

4. Girinsky T, Rey A, Roche B, Haie C, Gerbaulet A, Randrianarivello H., et al., Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys. 1993;27(5):1051-6.

2783

Digital Poster

SBRT versus ENRT for lymph-nodal relapses in gynecological cancers